
Please try another search
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Hagop M. Kantarjian | - | 2023 | Member of Clinical Advisory Board |
Changqing Ye | 53 | 2019 | Independent Non-Executive Director |
Shaomeng Wang | 58 | 2017 | Co-Founder, Chief Scientific Advisor & Non-Executive Director |
Dajun Yang | 60 | 2009 | Co-Founder, Chairman & CEO |
Allen S. Lichter | 77 | 2023 | Chairman of the Clinical Advisory Board |
Jedd D. Wolchok | - | 2021 | Member of Clinical Advisory Board |
Wei Ren | 43 | 2019 | Independent Non-Executive Director |
Asher A. Chanan-Khan | - | 2023 | Member of Clinical Advisory Board |
Jiuyun Yu | 59 | 2024 | Independent Non-Executive Director |
Marina S. Bozilenko | 59 | 2024 | Independent Non-Executive Director |
Hagop M. Kantarjian | - | 2023 | Member of Clinical Advisory Board |
Arul M. Chinnaiyan | - | - | Member of Clinical Advisory Board |
Dazhong Lu | 56 | 2018 | Independent Non-Executive Director |
Paul A. Bunn | 79 | - | Member of Clinical Advisory Board |
David Sidransky | 65 | 2021 | Independent Non-Executive Director |
Marc Estes Lippman | 80 | 2025 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review